Genmab A/S ADR (GMAB) News
Filter GMAB News Items
GMAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GMAB News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest GMAB News From Around the Web
Below are the latest news stories about GENMAB A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.
High Growth Tech Stocks To Watch In January 2025As global markets navigate a mixed start to the new year, with U.S. stocks closing out a strong 2024 despite recent economic data challenges such as the Chicago PMI contraction and revised GDP forecasts, investors are keeping a close eye on high growth tech stocks that could benefit from these shifting dynamics. In this environment, identifying promising tech companies often involves looking for those with robust innovation capabilities and adaptability to market changes, which can... |
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceMedia ReleaseCOPENHAGEN, Denmark; January 03, 2025Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco at 3:00 PM PST / 6:00 PM EST on January 14, 2025, 12:00 AM CET on January 15, 2025. The live and archived webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events-presentations. About Genmab Genmab is an international biotechno |
Genmab to Hold 2024 R&D Update and ASH Data Review MeetingMedia Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting today, December 11, 2024 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast. To register for the webcast, click https://genmab-post-ash-2024.open-exchange.net/. An archive of the webcast will be avai |
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)COPENHAGEN, Denmark, December 09, 2024--Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL). Results from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347), evaluating fixed-duration epcoritamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), |
Exploring None's High Growth Tech Stocks With Strong PotentialIn recent weeks, global markets have shown a mixed performance, with major U.S. indexes such as the S&P 500 and Nasdaq Composite reaching record highs, while the Russell 2000 Index for small-cap stocks experienced a decline following its previous outperformance. This divergence highlights the ongoing rally in growth stocks, particularly within sectors like information technology and consumer discretionary, which have gained over 3% amid broader economic indicators such as job growth... |
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary AnalysisMedia ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapyIn the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following treatment with e |
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R2)Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percentResults follow recent brea |
Capital Increase in Genmab as a Result of Employee Warrant ExerciseCompany Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 554 shares at DKK 962.00,3,436 shares at DKK 1,025.00,4,942 shares at DKK 1,032.00,305 shares at DKK 1,050.00, |
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated PersonsCompany Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading |
Why Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now?We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other high growth healthcare stocks. Global Healthcare Spending Trends and Investment Opportunities During lean economic times, investing in healthcare stocks is […] |